From Yahoo Finance: 2025-03-29 16:12:00

A discussion on the oversaturation of the biotech sector revealed that almost a quarter of biotech stocks have negative enterprise values, creating challenges for investors and companies. Analysts and investors are seeking a clear pathway for biotech to perform better, with suggestions to dissolve companies with negative values. However, biotech stocks hold promise with potential blockbuster drugs, though they come with risk. BridgeBio Pharma, Inc. (BBIO) stands out as a commercial-stage biopharmaceutical company with promising drugs like Attruby and infigratinib in its pipeline. BBIO ranks 9th on the list of best mid cap biotech stocks to buy.



Read more at Yahoo Finance: Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy